Skip to main content

Table 1 Cohort demographics and plasma biomarker values

From: A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

 

Cohort 1 (N = 37)

Cohort 2 (N = 94)

Cohort 3 (N = 121)

Cohort 4 (N = 26)

Cohort 5 (N = 96)

Cohort 6 (N = 40)

All Cohorts (N = 414)

Age

 Mean (SD)

73.1 (7.8)

71.1 (8.0)

66.1 (7.8)

75.1 (6.8)

71.4 (7.6)

69.7 (9.1)

70.0 (8.3)

 Min

59.2

56.7

47.0

66.1

45.0

46.1

45.0

 Max

87.5

93.1

85.0

88.9

89.0

86.0

93.1

Sex

 Male (%)

54.1%

58.5%

23.1%

57.7%

40.6%

35%

41.3%

Amyloid Positive (%)

49%

46%

17%

42%

49%

52%

39%

CDR

 Percent CDR = 0 [N]

- [0]

50% [94]

- [0]

56% [25]

- [0]

75% [40]

57.2% [159]

MMSE

 Percent MMSE = 27–30 [N]

45.9% [37]

- [0]

100% [121]

64% [25]

- [0]

85% [40]

84.3% [223]

Biomarker Used to Determine Brain Amyloid Status (% participants)

 PiB

68%

54%

52%

28%

 Amyvid

32%

22%

48%

19%

 Neuraceq

78%

18%

 CSF ELISA

100%

23%

 CSF IPMS

100%

46%

12%

ApoE Proteotype

 E2/E3 (%)

5.4%

8.5%

5.0%

23.1%

7.3%

7.5%

7.7%

 E2/E4 (%)

2.7%

6.4%

2.1%

5.0%

2.7%

 E3/E3 (%)

51.4%

46.8%

47.9%

46.2%

52.1%

45.0%

48.6%

 E3/E4 (%)

29.7%

28.7%

29.8%

19.2%

34.4%

35.0%

30.4%

 E4/E4 (%)

10.8%

9.6%

17.4%

11.5%

4.2%

7.5%

10.6%

C2N Plasma Aβ42/40

 Mean (SD)

0.089 (0.012)

0.102 (0.010)

0.101 (0.009)

0.096 (0.009)

0.087 (0.009)

0.100 (0.009)

0.097 (0.011)

 Min

0.065

0.084

0.080

0.082

0.059

0.080

0.059

 Max

0.113

0.148

0.126

0.114

0.113

0.117

0.148

  1. No patients had the E2/E2 genotype. Cohort 2 used Heparin tubes whereas all other cohorts used EDTA tubes for blood collection. [N] is the number of participants where data was available/provided
  2. CSF cerebrospinal fluid, ELISA enzyme-linked immunoassay, IPMS immunoprecipitation-mass spectrometry, CDR Clinical Dementia Rating, MMSE Mini-Mental State examination